Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease

Conditions: Diabetic Nephropathies; Kidney Failure, Chronic; Diabetes Mellitus Type 1; Heart Failure Interventions: Drug: Sotagliflozin; Drug: Placebo Sponsors: Alessandro Doria; Juvenile Diabetes Research Foundation; Canadian Institutes of Health Research (CIHR); The Kidney Foundation of Canada; The Cleveland Clinic; University of Washington; University of Michigan; University of Minnesota; University of Colorado, Denver; Northwestern University; Washington University School of Medicine; State University of New York - Upstate Medical University; Providence Medical Research Center; Stanford University; Montefiore Medical Center; University of Toronto; University Health Network, Toronto; University of Calgary; University of Alberta; University of British Columbia; Institut de Recherches Cliniques de Montreal; LMC Diabetes& Endocrinology Ltd.; Joslin Diabetes Center; Lexicon Pharmaceuticals; DexCom, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials